Key Highlights

  • Geron shares are down about 4.3% in pre-market trading, giving back part of Wednesday's post-earnings rally.
  • The stock jumped 21.64% in the prior regular session on Q2 2026 results.
  • Net product revenue for Rytelo grew 17% year over year to $57.5 million, beating consensus by nearly 4%.
  • Full-year 2026 Rytelo net product revenue guidance was raised to $220 million to $240 million.
  • The company reaffirmed operating expense guidance of $230 million to $240 million for the year.

Shares Give Back Some Post-Earnings Gains

Geron is trading modestly lower in pre-market action today, pulling back after a sharp rally in the prior session following the company's second-quarter earnings report. Shares fell as much as 5.52% to $1.54 in pre-market trading, after closing up 21.64% at $1.63 on Wednesday.

The company's Rytelo franchise continues to show strong demand growth. Net product revenue grew 17% year over year and 11% quarter over quarter to $57.5 million, with first-half 2026 net revenue up approximately 24% versus the same period in 2025, even as total 2026 first-half revenue decreased 4% year over year.

Guidance Raised as Prescriber Base Expands

Management raised full-year 2026 Rytelo net product revenue guidance to a range of $220 million to $240 million and reaffirmed full-year operating expense guidance in the range of $230 million to $240 million, with expected deductions from gross product revenue in the low 20s percent range.

Commercially, Rytelo achieved 5% demand growth quarter over quarter, an 8% increase in prescribing accounts to approximately 1,575 accounts since launch, and 34% first and second line patient starts on a rolling 12-month basis. The company estimates more than 8,000 eligible second line lower risk MDS patients remain in the United States and plans to share European commercialization plans before year end.

About Geron

Geron is a commercial-stage biopharmaceutical company headquartered in Foster City, California, focused on transforming the treatment of myeloid hematologic malignancies through telomerase inhibition. The company's flagship product, Rytelo, is a first-in-class oligonucleotide telomerase inhibitor with FDA and European Union approval for treating adult patients with lower-risk myelodysplastic syndromes who require transfusion support.

Phase 3 Trial Update

Geron is also evaluating a modification to the event threshold for the interim analysis in its Phase 3 IMpactMF trial after regulatory discussions, with projected timelines remaining unchanged. Based case progression to the final overall survival analysis in the second half of 2027 remains the expectation, though an earlier positive interim outcome would represent an upside scenario for the trial's timing.

Trading Context

Wednesday's 21.64% rally pushed shares to $1.63, within a 52-week range of $1.04 to $2.01 and still below the high end of that range. Today's pre-market pullback to around $1.54 remains above the $1.34 level shares traded at prior to the earnings release, indicating the stock retains most of its post-earnings gains even after the pullback.

Conclusion

Geron's pre-market pullback reflects some profit taking after a substantial post-earnings rally, rather than any negative development. With Rytelo demand accelerating and guidance raised for the year, the underlying commercial trajectory of the business remains strong heading into the back half of 2026.

Why is Geron stock down today?

Shares are pulling back after a sharp 21.64% rally in the prior session, representing a partial giveback of post-earnings gains rather than new negative news.

What was Geron's Q2 2026 Rytelo revenue?

Net product revenue for Rytelo grew 17% year over year to $57.5 million, beating consensus estimates.

Did Geron raise its guidance?

Yes. The company raised full-year 2026 Rytelo net product revenue guidance to a range of $220 million to $240 million.

This article is for informational purposes only and does not constitute financial, investment, or trading advice. Readers should conduct their own research or consult a licensed financial advisor before making any investment decisions.